Abstract
Basal cell carcinoma (BCC) accounts for almost 80% of skin cancers, and its healthcare workload burden is substantial within dermatology departments. Although most BCCs are small, well-defined tumors amenable of surgery or conservative procedures, in a small proportion of patients, BCCs can progress to an advanced stage including locally advanced BCC. The goal of the clinician in the treatment of BCC should be the right therapeutic approach at diagnosis, and different guidelines propose treatment strategies in order to prevent relapses or disease progression. In case of unresectable and untreatable BCC with radiotherapy, the first-choice medical therapy is Hedgehog-GLI (HH) pathway inhibitors. Sonidegib was approved by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) as a first-line treatment for adult patients with locally advanced BCC, becoming the second HH pathway inhibitor receiving approval after vismodegib. In this review, data on pharmacology, safety, tolerability, and efficacy of sonidegib are summarized and compared to those of vismodegib. Lastly, indications on the management of advanced basal cell carcinoma based on author's clinical experience are provided.
References
Feb 9, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Richard A GrahamPatricia M Lorusso
Apr 20, 2011·Nature Reviews. Genetics·Philip W InghamClaudia Seger
Jul 15, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Patricia M LorussoRichard A Graham
Mar 31, 2012·British Journal of Clinical Pharmacology·Richard A GrahamMark J Dresser
Feb 14, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jordi RodonAlain C Mita
May 13, 2014·Cancer Chemotherapy and Pharmacology·Markus ZollingerPiet Swart
Jun 10, 2010·ACS Medicinal Chemistry Letters·Shifeng PanMarion Dorsch
Sep 11, 2014·Annals of Neurosciences·Zia ChoudhryNusrat Jahan Mobassarah
May 20, 2015·Journal of the American Academy of Dermatology·Aleksandar SekulicUNKNOWN ERIVANCE BCC investigators
May 20, 2015·The Lancet Oncology·Michael R MigdenReinhard Dummer
Sep 2, 2015·Drugs·Celeste B Burness
Jan 20, 2016·CPT: Pharmacometrics & Systems Pharmacology·T LuJ Y Jin
Feb 24, 2016·Cancer Chemotherapy and Pharmacology·Varun GoelDalila Sellami
Apr 21, 2016·Journal of Clinical Pharmacology·Jocelyn ZhouDalila Sellami
Jun 10, 2016·British Journal of Clinical Pharmacology·Jocelyn ZhouDalila Sellami
Sep 25, 2016·European Journal of Clinical Pharmacology·Michelle QuinlanDalila Sellami
Jan 27, 2017·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Heidi J EinolfSam Rebello
Feb 22, 2017·The British Journal of Dermatology·J A C VerkouterenT Nijsten
May 18, 2017·BMC Cancer·Aleksandar SekulicUNKNOWN ERIVANCE BCC Investigators
Jun 4, 2017·Clinical Pharmacokinetics·Yves HorsmansRichard A Preston
Aug 29, 2017·Journal of the European Academy of Dermatology and Venereology : JEADV·J T LearR Dummer
Feb 7, 2018·Cancer Treatment Reviews·Michael R MigdenJohn T Lear
Sep 13, 2018·CA: a Cancer Journal for Clinicians·Freddie BrayAhmedin Jemal
Dec 19, 2018·Cells·Silvia Pietrobono, Barbara Stecca
Jan 17, 2019·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Richard L Carpenter, Haimanti Ray
Mar 14, 2019·The British Journal of Dermatology·Z C VenablesI M Leigh
Jul 10, 2019·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Ketty PerisUNKNOWN European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Rese
Jan 29, 2020·Journal of the European Academy of Dermatology and Venereology : JEADV·R DummerR J J Grob
Sep 2, 2020·Dermatologic Therapy·Alessia VillaniMassimiliano Scalvenzi